Announcements Trials
Browse Landscape

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 59Carcinoma, Hepatocellular 46Colorectal Neoplasms 33Stomach Neoplasms 31Esophageal Squamous Cell Carcinoma 27Squamous Cell Carcinoma of Head and Neck 20Esophageal Neoplasms 14Small Cell Lung Carcinoma 13Neoplasm Metastasis 13Lung Neoplasms 13Rectal Neoplasms 12Head and Neck Neoplasms 12Advanced Solid Tumor 12Triple Negative Breast Neoplasms 11Cholangiocarcinoma 11Nasopharyngeal Carcinoma 10Melanoma 10Uterine Cervical Neoplasms 9Recurrence 9Neoplasms 9Colonic Neoplasms 9Pancreatic Neoplasms 7Urinary Bladder Neoplasms 6Solid Tumor 6Carcinoma, Transitional Cell 6Breast Neoplasms 6Sarcoma 5Lymphoma, Extranodal NK-T-Cell 5Lymphoma 5Hodgkin Disease 5

Interventions

Dexamethasone 3iniparib 2Ultrasonography 2Poly(ADP-ribose) Polymerase Inhibitors 2Calcium Dobesilate 2Blood Specimen Collection 2tislelizumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1asparaginase erwinia chrysanthemi recombinant 1amminedichloro(2-methylpyridine)platinum(II) 1ZD4054 1Vincristine 1Sodium Chloride 1Rituximab 1Paclitaxel 1Narrow Band Imaging 1Methotrexate 1Mammography 1Lenalidomide 1Immune Checkpoint Inhibitors 1High-Energy Shock Waves 1Doxorubicin 1Dexrazoxane 1Cytarabine 1Cetirizine 1Carboplatin 1BNT162 Vaccine 1Asparaginase 12019-nCoV Vaccine mRNA-1273 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hypersensitivity × tislelizumab × Clear all
NCT06448169 2024-06-07

Observational Study on the Sensitivity of Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancer

Shandong University

Unknown
200 enrolled
Breast

Hypersensitivity, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡